Rakuten on January 10
Zhengye Biotechnology Holding Limited (Zhengye Bio) recently submitted a prospectus to be listed on the NASDAQ in the United States.
Zhengye Biotech has obtained the notice of filing for overseas issuance and listing. Zhengye Biotech intends to issue no more than 1,312,908 ordinary shares.
Zhengye Biotech is one of the first enterprises designated by the Ministry of Agriculture to produce highly pathogenic porcine PRRS inactivated vaccine and rabies purified lyophilized inactivated vaccine (Flury Lep strain), and is designated by the Ministry of Agriculture to produce swine fever splenic gossip attenuated vaccine.
According to the prospectus, the prospectus shows that Zhengye Bio's revenue in 2021 and 2022 will be 21.4 billion yuan, 2600 million yuan;The operating profit was 52.38 million yuan and 65.83 million yuan respectivelyThe net profit was 46.47 million yuan and 55.74 million yuan respectively.
Zhengye Biotech's revenue in the first half of 2023 is 11.7 billion yuan (about 1611..)$50,000), with revenue of $12.3 billion yuan (US$17.01 million);
Zhengye Biotech's net profit in 2023 will be 24.07 million yuan (about 3.32 million US dollars), compared with 27.55 million yuan (about 3.8 million US dollars) in the same period last year.
Before the IPO, Zhenfa Han held 975818%, Wei Lian holds 01819%, Yawen Dong holds 02728%, Yuyou He holds 01096%。
Lei Di was founded by ** Lei Jianping, if ** please in**.